Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 30Neoplasm Metastasis 3Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 2Metastatic Castration-resistant Prostate Cancer 2Urologic Diseases 1Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Radiation Injuries 1Prostatic Diseases 1Prostate Cancer Metastatic 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oligometastatic Prostate Cancer 1Neoplasm Recurrence, Local 1Metastatic Hormone Sensitive Prostate Cancer 1Metastatic Castrate-sensitive Prostate Cancer 1Hormone Sensitive Prostate Cancer 1Genital Neoplasms, Male 1Gastrointestinal Diseases 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Fulvestrant 63Letrozole 53Paclitaxel 49Trastuzumab 41pembrolizumab 40ribociclib 37Specimen Handling 37palbociclib 36Capecitabine 34Carboplatin 33Anastrozole 33Tamoxifen 32exemestane 29pertuzumab 28abemaciclib 28Magnetic Resonance Spectroscopy 26Cyclophosphamide 26trastuzumab deruxtecan 24Surveys and Questionnaires 21Radiotherapy 18Biopsy 18olaparib 17Standard of Care 16Docetaxel 16Blood Specimen Collection 16Taxes 14Mastectomy, Segmental 14eribulin 13elacestrant 13130-nm albumin-bound paclitaxel 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Androgen Antagonists × 90 days × Clear all
NCT07340541 2026-05-20

EVOLVE-BDT

UNC Lineberger Comprehensive Cancer Center

Phase 2 Recruiting
700 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡